An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

[1]  Benjamin G. Bitler,et al.  Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations , 2016, Molecular & cellular oncology.

[2]  Y. Miyagi,et al.  Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. , 2013, Journal of proteome research.

[3]  Jeong-Won Lee,et al.  Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. , 2013, Human pathology.

[4]  I. Shih,et al.  Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. , 2012, Human pathology.

[5]  Kenichi Tanaka,et al.  Histology‐specific long‐term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: A population‐based study from 1983 to 2007 in Niigata , 2012, The journal of obstetrics and gynaecology research.

[6]  J. Blaakaer,et al.  The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. , 2012, Gynecologic oncology.

[7]  D. Bowtell,et al.  Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers , 2011, PloS one.

[8]  A. Tinker,et al.  Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. , 2011, Gynecologic oncology.

[9]  Mitsuaki Suzuki,et al.  Less Impact of Adjuvant Chemotherapy for Stage I Clear Cell Carcinoma of the Ovary: A Retrospective Japan Clear Cell Carcinoma Study , 2010, International Journal of Gynecologic Cancer.

[10]  R. Burger,et al.  Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary , 2010, Molecular Cancer Therapeutics.

[11]  D. Huntsman,et al.  Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[12]  S. Murphy,et al.  Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes , 2010, Oncogene.

[13]  T. Psaltopoulou,et al.  Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum‐paclitaxel chemotherapy , 2010, Cancer.

[14]  N. Horowitz,et al.  When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. , 2010, Gynecologic oncology.

[15]  V. Heinemann,et al.  UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? , 2009, Anti-cancer drugs.

[16]  J. Chan,et al.  Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. , 2008, Gynecologic oncology.

[17]  R. Ozols,et al.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Royston,et al.  A New Proposal for Multivariable Modelling of Time‐Varying Effects in Survival Data Based on Fractional Polynomial Time‐Transformation , 2007, Biometrical journal. Biometrische Zeitschrift.

[19]  J. Thigpen.  Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma , 2006 .

[20]  M. Dimopoulos,et al.  Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. , 2006, Gynecologic oncology.

[21]  M. Dimopoulos,et al.  Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. , 2005, Gynecologic oncology.

[22]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[23]  N. Collins,et al.  Modulation of paclitaxel resistance by annexin IV in human cancer cell lines , 2000, British Journal of Cancer.

[24]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[25]  J. Cain,et al.  Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. , 1996, Gynecologic oncology.

[26]  P. Russell.  Surface Epithelial—Stromal Tumors of the Ovary , 1994 .

[27]  E. Yordan,et al.  Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.